Fri, Feb 27, 2015, 9:22 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Synergy Pharmaceuticals, Inc. Message Board

  • hawk25702 hawk25702 Sep 26, 2013 8:01 PM Flag

    I pat myself on the back for not replying harshly to Rtg.....

    Think of all positive articles on the SGYP progression on its oncoming presentations to the FDA and all someone can do is dredge up some negative article that doesn't have substance....arrgh! I'd brought Rtg back but now and for eternity he/she goes to ignore land. Linzmess and Rtg can get nice and cosy and I'm not bringing either one back....

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • LIE #2 of the day. This one digged up from the archives. I do agree half the patients probably discontinue Linzmess, and will Plecanatide too, in the real world...but in clinical trials only 5% discontinued due to diarrhea and 3% for Plecanatide. A car cry from the LIE that hawk is posting on here to prop up the stock price for other investors. I'm beggining to think you guys all work for SGYP are not actual investors.

      -----------------------------------------------------------

      I'm sure 37.5% of those in the IRWD study would beg to differ...lol.
      Anyway, IRWD will be having runaway diarrhea soon as Plecanatide hits the market.......to tell the truth, I think 37.5% is a little low to what the % of public will be experiencing with Linzess.....on the plus side, grocery store sales of toilet paper will soar to all time highs while Linzess is on the market. And the public, given the choice of no matter what percent higher diarrhea.......is going to opt for Linzess? Keep dreamin Pal. Less

 
SGYP
3.02+0.04(+1.34%)Feb 27 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.